Evaluation of Amodiaquin (Camoquin) in the Treatment of Relapsing Vivax Malaria

Love, Julian; Foulk, Richard; Williams, Robert G. W.; Mitchell, Ronald B.

doi:10.1097/00000441-195301000-00005

Cited by 9 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chloroquineresistant malaria is increasingly common in east Africa (Brandling-Bennett et al, 1988), and has been documented in Zambia and Nigeria. However, (Booth et al, 1967;Glick, 1957;Kennedy, 1955;Lind et al, 1973;Love et al, 1953;Perry et al, 1962) and hepatitis (Bepler et al, 1959;Pomeroy et al, 1959) have appeared since the drug's first use. In 1986 several reports of serious reactions to prophylactic AQ (Carr, 1986;Hatton et al, 1986;Neftel et al, 1986;Rhodes et al, 1986) caused the principal manufacturer to withdraw the compound from preventative use, and to date there have been no reports of serious toxicity to AQ in malaria patients.…”

Section: Discussionmentioning

confidence: 99%

The disposition of amodiaquine in Zambians and Nigerians with malaria.

Winstanley

Simooya

Kofiekue

et al. 1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Oral amodiaquine (AQ) has been used to treat patients with symptomatic malaria in Zambia (n = 14) and Nigeria (n = 5). Clinical cure was obtained in all patients and no serious adverse drug reactions were seen. 2 As in healthy subjects, AQ achieved low plasma concentrations. Plasma concentration vs time profiles of desethylamodiaquine (AQm) from the present study did not differ from those obtained from healthy subjects. 3 In contrast to previous results from healthy subjects, the mean ratio of red cell (RBC) plasma AQm concentration in the present study was 0.80 : 1 at the start of the study and rose in a linear manner (r = 0.873; P < 0.01) to 3.04: 1 by the end (n = 10; P < 0.01). The final mean value was similar to that seen in healthy subjects. 4 These data show that there are differences in the disposition of orally administered AQ between healthy subjects and patients with clinical malaria. The relevance of this observation to the frequency of adverse reactions to AQ in these two groups is not established.

show abstract